Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the recipient of a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 1,900 shares, a decrease of 24.0% from the July 15th total of 2,500 shares. Based on an average daily volume of 62,800 shares, the days-to-cover ratio is presently 0.0 days.

Santen Pharmaceutical Stock Up 0.2 %

SNPHY stock traded up $0.03 during midday trading on Friday, reaching $12.10. 2,428 shares of the company’s stock traded hands, compared to its average volume of 7,929. The stock’s 50-day moving average is $10.99 and its 200 day moving average is $10.27. Santen Pharmaceutical has a 52-week low of $8.31 and a 52-week high of $12.94.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.